China H1N1 Flu Vaccine Maker Says Passed Phase I Trial
This article was originally published in PharmAsia News
Executive SummarySinovac Biotech of China said its H1N1 flu vaccine has passed a Phase I trial without severe adverse reactions for as long as three days after inoculation. The company plans to publish a preliminary report on its vaccine by mid-August. Sinovac, also known as Beijing Kexing Bioproducts, expects to complete trials in mid-September, testing it on a range of ages from 3 years old to 60 years old. (Click here for more
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.